Pharmacokineticsand pharmacodynamics of GSK2190915 in healthy Japanese subjects. (a) Mean plasma concentration vs. time profiles for GSK2190915 following single dose administration of 10 mg (), 50 mg (), 150 mg () or 200 mg () GSK2190915. (B) Median (plus interquartile range) percentage changes from baseline plasma LTB4 following single dose administration of placebo () or 10 mg (), 50 mg (), 150 mg () or 200 mg () GSK2190915. (C) Median (plus interquartile range) of LTE4 excretion in urine as a percentage of the pre‐dose value following single dose administration of placebo () or 10 mg (), 50 mg (), 150 mg () or 200 mg () GSK2190915.